Relugolix

Overview

Relugolix, also known as TAK-385, is a luteinizing hormone-releasing hormone (LH-RH) receptor antagonist administered orally. By preventing LH-RH from binding with the LH-RH receptor in the anterior pituitary gland and suppressing the secretion of luteinizing hormone (LH) and follicle stimulation hormone (FSH) from the anterior pituitary gland, TAK-385 controls the effect of LH and FSH on the ovary, reduces the level of estrogen in blood, which is known to be associated with the development of endometriosis and uterine fibroids, and is expected to improve the symptoms of these disorders.

Application

Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | GNRH Receptor

Product Information

• Catalog No.: B0084-462794
• CAS No.: 737789-87-6
• Molecular Formula: C29H27F2N7O5S
• Molecular Weight: 623.63
• Purity: ≥95%
• Storage: Store at -20°C
• Solubility: Soluble in DMF, DMSO, Ethanol, Ethyl acetate, Tetrahydrofuran

Source

Original product source